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on consolidation CT. Thirteen trials used cisplatin+vinca alkaloid/eto-
poside, 1 used carboplatin+taxane, 2 used other platinum regimens, 
3 used vinca-alkaloid and 3 used other non platinum regimens. There 
was a signiﬁcant beneﬁt of sequential CT on survival (HR=0.88, 95% 
CI=[0.82-0.94], p=0.0001), with an absolute beneﬁt of 2.6% (from 
8.7% to 11.3%) at 3 years. There was no clear evidence of a difference 
in effect by type or timing of CT. Nor was there clear evidence that any 
patient subgroup deﬁned by age, sex, performance status, histology or 
stage beneﬁted more or less from sequential CT.
21 RCTs were eligible for the meta-analysis of concomitant CT. 
IPD was received from 15 RCTs (2733 patients) and only survival 
HR from one RCT (177 patients, IPD soon available). The survival 
analysis was based on these 16 trials and 2910 patients (87% of all 
known randomised patients). This adds 7 trials (1145 patients) to the 
previous analysis. The progression-free survival (PFS) analysis was 
based on 12 trials and 2034 patients. Median follow-up was 5.3 years. 
Nine trials used cisplatin or carboplatin alone, 3 used cisplatin or 
carboplatin+etoposide, 1 used carboplatin+taxane and 3 used taxane 
alone. In 4 trials, induction CT was added in both arms. There was 
a signiﬁcant beneﬁt of concomitant CT on survival (HR=0.88, 95% 
CI=[0.81-0.95], p=0.0008), with an absolute beneﬁt of 3.2% (from 
13.4% to 16.6%) at 3 years. Exclusion of trials with incomplete data 
did not change the results. There was a signiﬁcant beneﬁt of concomi-
tant CT on PFS (HR=0.81, 95% CI=[0.74-0.89], p<0.0001). There was 
no clear evidence that any patient subgroup beneﬁted more or less from 
concomitant CT.
Conclusions: These results demonstrate now a beneﬁt of sequential 
and concomitant CT in locally advanced NSCLC treated by RT. They 
provide robust estimates for future policies and research.
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Background: The previous IPD meta-analyses of CT in locally ad-
vanced NSCLC indicated that adding sequential CT to radiotherapy im-
proved survival (BMJ 1995;311:899) and that adding concomitant CT 
to radiotherapy could also improve survival (Ann Oncol 2006;17:473). 
The NSCLC Collaborative Group performed a meta-analysis of RCTs 
that compared concomitant RT-CT versus sequential RT-CT.
Methods: Systematic searches for RCTs were followed by the central 
collection, checking and re-analysis of updated IPD. Results from 
individual trials were combined using the stratiﬁed (by trial) log-rank 
test to calculate pooled hazard ratios (HRs). The primary outcome was 
overall survival, secondary outcomes were progression-free survival 
(PFS), cumulative incidences of loco-regional progression and of 
distant progression and acute toxicity (haematological, pulmonary, 
oesophageal).
Results: Seven trials which randomized 1,301 patients were eligible for 
the meta-analysis. IPD was received from 1,114 patients from 5 RCTs 
(86% of all known randomised patients). The HR for overall survival 
was also provided for one RCT (85 patients, IPD soon available). The 
main survival analysis was based on these 6 trials and 1,199 patients 
(92% of all randomized patients). Median follow-up was 5 years. The 
PFS analyses were based on the 5 trials with IPD. Two trials used same 
drugs and doses for concomitant and sequential CT. For sequential CT, 
all trials used at least cisplatin, induction CT was used in 5 trials and 
consolidation CT in one. For concomitant CT, cisplatin was used in 5 
trials with daily administration in 2 trials, and carboplatin was used in 
one trial. One trial used consolidation CT after concomitant CT. RT 
dose was lower than 60 Gy in 2 trials and RT was different between 
the two arms in one trial (same total dose but split course used in the 
concomitant arm).
Concomitant RT-CT increased acute oesophageal toxicity (grade 
3-4) from 3% to 18% with a relative risk of 5.7 (95% CI=[3.5-9.5], 
p<0.0001). There was no signiﬁcant difference between concomitant 
and sequential RT-CT for pulmonary acute toxicity. Haematological 
toxicity rates were highly variable among trials and the data were not 
pooled.
There was a signiﬁcant beneﬁt of concomitant RT-CT as compared 
to sequential RT-CT on survival (HR=0.83, 95% CI=[0.73-0.94], 
p=0.0026), with an absolute beneﬁt of 6.6% (from 18.2% with sequen-
tial RT-CT to 24.8% with concomitant RT-CT) at 3 years. For progres-
sion-free survival, the HR was 0.89 (95% CI=[0.78-1.00], p=0.0585). 
Concomitant CT decreased loco-regional progression (HR=0.76, 95% 
CI=[0.62-0.94], p=0.011), but its effect was not different from that of 
sequential CT on distant progression (HR=1.04, 95% CI=[0.86-1.25], 
p=0.669). There was no clear evidence of a difference in effect by type 
of CT. Nor was there clear evidence that any patient subgroup deﬁned 
by age, sex, performance status, histology or stage beneﬁted more or 
less from concomitant CT. 
Conclusions: Concomitant RT-CT, as compared to sequential RT-
CT, improved survival of patients with locally advanced NSCLC, 
mainly due to the decrease of loco-regional progression, at the cost of 
increased acute oesophageal toxicity.
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